Trials / Conditions / Zollinger Ellison Syndrome

Zollinger Ellison Syndrome

11 registered clinical trials studyying Zollinger Ellison Syndrome.

Status	Trial	Sponsor	Phase
Withdrawn	Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine NCT02831179	Vanderbilt-Ingram Cancer Center	Phase 1
Completed	A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Relate NCT02153398	AstraZeneca	Phase 3
Terminated	YF476 and Type II Gastric Carcinoids NCT02454075	Trio Medicines Ltd.	Phase 2
Completed	Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zolli NCT00079833	AstraZeneca	Phase 3
Completed	Treatment of Zollinger-Ellison Syndrome With Prevacid NCT00204373	Charles Mel Wilcox, MD	Phase 4
Completed	Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome NCT00001254	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	—
Completed	Treatment of Zollinger-Ellison Syndrome NCT00001241	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	—
Completed	Evaluating Patients With Abnormal Levels of Gastric Acid NCT00001240	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	—
Completed	Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer NCT00001228	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2
Completed	The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid NCT00001191	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2
Completed	Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas NCT00001165	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2